Cargando…

Comparative Efficacy of Targeted Therapies in Patients with Non-Small Cell Lung Cancer: A Network Meta-Analysis of Clinical Trials

This study aims to investigate the efficacy of targeted therapies in the treatment of non-small cell lung cancer (NSCLC) by using a network meta-analysis of clinical trials. PubMed, EMBASE, Cochrane Library, and Clinicaltrials.gov were searched by using keywords related to the topic on 19 September...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoang, Tung, Myung, Seung-Kwon, Pham, Thu Thi, Kim, Jeongseon, Ju, Woong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230601/
https://www.ncbi.nlm.nih.gov/pubmed/32283699
http://dx.doi.org/10.3390/jcm9041063
_version_ 1783534992687628288
author Hoang, Tung
Myung, Seung-Kwon
Pham, Thu Thi
Kim, Jeongseon
Ju, Woong
author_facet Hoang, Tung
Myung, Seung-Kwon
Pham, Thu Thi
Kim, Jeongseon
Ju, Woong
author_sort Hoang, Tung
collection PubMed
description This study aims to investigate the efficacy of targeted therapies in the treatment of non-small cell lung cancer (NSCLC) by using a network meta-analysis of clinical trials. PubMed, EMBASE, Cochrane Library, and Clinicaltrials.gov were searched by using keywords related to the topic on 19 September 2018. Two investigators independently selected relevant trials by pre-determined criteria. A pooled response ratio (RR) for overall response rate (ORR) and a hazard ratio (HR) for progression-free survival (PFS) were calculated based on both the Bayesian and frequentist approaches. A total of 128 clinical trials with 39,501 participants were included in the final analysis of 14 therapeutic groups. Compared with chemotherapy, both ORR and PFS were significantly improved for afatinib, alectinib, and crizotinib, while only PFS was significantly improved for cabozantinib, ceritinib, gefitinib, and osimertinib. Consistency was observed between the direct and indirect comparisons based on the Bayesian approach statistically and the frequentist approach visually. Cabozantinib and alectinib showed the highest probability for the first-line treatment ranking in ORR (62.5%) and PFS (87.5%), respectively. The current network meta-analysis showed the comprehensive evidence-based comparative efficacy of different types of targeted therapies, which would help clinicians use targeted therapies in clinical practice.
format Online
Article
Text
id pubmed-7230601
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72306012020-05-22 Comparative Efficacy of Targeted Therapies in Patients with Non-Small Cell Lung Cancer: A Network Meta-Analysis of Clinical Trials Hoang, Tung Myung, Seung-Kwon Pham, Thu Thi Kim, Jeongseon Ju, Woong J Clin Med Article This study aims to investigate the efficacy of targeted therapies in the treatment of non-small cell lung cancer (NSCLC) by using a network meta-analysis of clinical trials. PubMed, EMBASE, Cochrane Library, and Clinicaltrials.gov were searched by using keywords related to the topic on 19 September 2018. Two investigators independently selected relevant trials by pre-determined criteria. A pooled response ratio (RR) for overall response rate (ORR) and a hazard ratio (HR) for progression-free survival (PFS) were calculated based on both the Bayesian and frequentist approaches. A total of 128 clinical trials with 39,501 participants were included in the final analysis of 14 therapeutic groups. Compared with chemotherapy, both ORR and PFS were significantly improved for afatinib, alectinib, and crizotinib, while only PFS was significantly improved for cabozantinib, ceritinib, gefitinib, and osimertinib. Consistency was observed between the direct and indirect comparisons based on the Bayesian approach statistically and the frequentist approach visually. Cabozantinib and alectinib showed the highest probability for the first-line treatment ranking in ORR (62.5%) and PFS (87.5%), respectively. The current network meta-analysis showed the comprehensive evidence-based comparative efficacy of different types of targeted therapies, which would help clinicians use targeted therapies in clinical practice. MDPI 2020-04-09 /pmc/articles/PMC7230601/ /pubmed/32283699 http://dx.doi.org/10.3390/jcm9041063 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hoang, Tung
Myung, Seung-Kwon
Pham, Thu Thi
Kim, Jeongseon
Ju, Woong
Comparative Efficacy of Targeted Therapies in Patients with Non-Small Cell Lung Cancer: A Network Meta-Analysis of Clinical Trials
title Comparative Efficacy of Targeted Therapies in Patients with Non-Small Cell Lung Cancer: A Network Meta-Analysis of Clinical Trials
title_full Comparative Efficacy of Targeted Therapies in Patients with Non-Small Cell Lung Cancer: A Network Meta-Analysis of Clinical Trials
title_fullStr Comparative Efficacy of Targeted Therapies in Patients with Non-Small Cell Lung Cancer: A Network Meta-Analysis of Clinical Trials
title_full_unstemmed Comparative Efficacy of Targeted Therapies in Patients with Non-Small Cell Lung Cancer: A Network Meta-Analysis of Clinical Trials
title_short Comparative Efficacy of Targeted Therapies in Patients with Non-Small Cell Lung Cancer: A Network Meta-Analysis of Clinical Trials
title_sort comparative efficacy of targeted therapies in patients with non-small cell lung cancer: a network meta-analysis of clinical trials
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230601/
https://www.ncbi.nlm.nih.gov/pubmed/32283699
http://dx.doi.org/10.3390/jcm9041063
work_keys_str_mv AT hoangtung comparativeefficacyoftargetedtherapiesinpatientswithnonsmallcelllungcanceranetworkmetaanalysisofclinicaltrials
AT myungseungkwon comparativeefficacyoftargetedtherapiesinpatientswithnonsmallcelllungcanceranetworkmetaanalysisofclinicaltrials
AT phamthuthi comparativeefficacyoftargetedtherapiesinpatientswithnonsmallcelllungcanceranetworkmetaanalysisofclinicaltrials
AT kimjeongseon comparativeefficacyoftargetedtherapiesinpatientswithnonsmallcelllungcanceranetworkmetaanalysisofclinicaltrials
AT juwoong comparativeefficacyoftargetedtherapiesinpatientswithnonsmallcelllungcanceranetworkmetaanalysisofclinicaltrials